| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
19,802 |
14,062 |
$3.28M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
9,639 |
6,861 |
$2.33M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
15,646 |
12,022 |
$2.01M |
| 80053 |
Comprehensive metabolic panel |
28,478 |
21,079 |
$1.22M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,942 |
1,682 |
$594K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
8,130 |
6,295 |
$552K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
2,018 |
1,717 |
$533K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
2,509 |
1,512 |
$520K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,761 |
2,432 |
$470K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
33,431 |
24,119 |
$436K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
8,893 |
6,823 |
$352K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
3,053 |
2,295 |
$291K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,886 |
2,403 |
$269K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
7,660 |
5,516 |
$251K |
| 87040 |
|
4,090 |
2,614 |
$232K |
| 71045 |
Radiologic examination, chest; single view |
8,461 |
6,215 |
$225K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
4,449 |
3,297 |
$222K |
| 81001 |
|
13,732 |
10,907 |
$203K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
497 |
421 |
$198K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
2,019 |
1,040 |
$189K |
| 84484 |
|
7,704 |
5,070 |
$180K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
359 |
302 |
$177K |
| 84443 |
Thyroid stimulating hormone (TSH) |
5,873 |
5,296 |
$175K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
5,145 |
3,642 |
$163K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
1,943 |
1,708 |
$151K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
6,125 |
4,756 |
$147K |
| 36415 |
Collection of venous blood by venipuncture |
35,847 |
25,542 |
$145K |
| 83690 |
|
5,882 |
4,623 |
$126K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,286 |
1,898 |
$122K |
| 71046 |
Radiologic examination, chest; 2 views |
3,001 |
2,649 |
$121K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
835 |
593 |
$111K |
| 80061 |
Lipid panel |
3,651 |
3,344 |
$111K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,597 |
3,097 |
$104K |
| 83880 |
|
2,083 |
1,719 |
$104K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
3,599 |
2,749 |
$102K |
| G0378 |
Hospital observation service, per hour |
1,070 |
477 |
$97K |
| 93017 |
|
428 |
366 |
$87K |
| 84703 |
|
1,712 |
1,422 |
$87K |
| 96376 |
|
2,200 |
1,291 |
$86K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
375 |
334 |
$81K |
| 84439 |
|
2,003 |
1,832 |
$78K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,039 |
953 |
$77K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
877 |
845 |
$77K |
| 83735 |
|
5,166 |
4,104 |
$76K |
| 76770 |
|
532 |
473 |
$67K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,143 |
731 |
$60K |
| 85379 |
|
1,236 |
1,053 |
$55K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,688 |
1,358 |
$54K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
504 |
450 |
$54K |
| 71250 |
|
238 |
225 |
$50K |
| 72110 |
|
574 |
541 |
$48K |
| 76830 |
Ultrasound, transvaginal |
395 |
360 |
$47K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
568 |
439 |
$46K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,351 |
2,228 |
$46K |
| J2704 |
Injection, propofol, 10 mg |
3,472 |
2,015 |
$43K |
| 85610 |
|
3,835 |
2,945 |
$41K |
| 83605 |
|
5,747 |
4,363 |
$40K |
| 73562 |
|
923 |
791 |
$39K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
175 |
87 |
$38K |
| 86140 |
|
1,397 |
1,200 |
$36K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
80 |
52 |
$36K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,426 |
912 |
$36K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
257 |
239 |
$36K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
390 |
331 |
$35K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
83 |
78 |
$34K |
| 73030 |
|
1,002 |
846 |
$33K |
| 94664 |
|
515 |
362 |
$32K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
800 |
633 |
$32K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
309 |
155 |
$31K |
| 73630 |
|
844 |
704 |
$29K |
| 82607 |
|
701 |
621 |
$28K |
| 82803 |
|
1,184 |
942 |
$28K |
| 85027 |
|
2,799 |
2,148 |
$25K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
640 |
509 |
$24K |
| 93971 |
|
337 |
316 |
$23K |
| 73610 |
|
669 |
533 |
$23K |
| 84702 |
|
401 |
298 |
$22K |
| 76536 |
|
221 |
205 |
$22K |
| 85730 |
|
1,977 |
1,708 |
$22K |
| 82550 |
|
1,781 |
1,427 |
$21K |
| 74018 |
|
479 |
444 |
$20K |
| 73130 |
|
452 |
367 |
$19K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
306 |
276 |
$18K |
| 74019 |
|
197 |
155 |
$18K |
| 73110 |
|
434 |
321 |
$17K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,082 |
1,238 |
$17K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
6,217 |
4,713 |
$15K |
| 82570 |
|
643 |
600 |
$15K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
5,520 |
3,970 |
$14K |
| J2785 |
Injection, regadenoson, 0.1 mg |
101 |
93 |
$14K |
| 82553 |
|
266 |
202 |
$14K |
| 72050 |
|
174 |
158 |
$13K |
| 80179 |
|
187 |
161 |
$13K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,551 |
1,183 |
$13K |
| 85651 |
|
789 |
685 |
$13K |
| 80143 |
|
188 |
165 |
$13K |
| 86850 |
|
587 |
511 |
$12K |
| 96367 |
|
348 |
281 |
$12K |
| 20610 |
|
240 |
108 |
$12K |
| 76642 |
|
120 |
116 |
$11K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
25 |
25 |
$11K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
186 |
149 |
$11K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
390 |
328 |
$11K |
| 84466 |
|
304 |
288 |
$10K |
| 86901 |
|
626 |
547 |
$9K |
| 86900 |
|
626 |
547 |
$9K |
| 83540 |
|
669 |
610 |
$9K |
| 36600 |
|
293 |
228 |
$9K |
| 87147 |
|
399 |
351 |
$9K |
| 87081 |
|
324 |
285 |
$8K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
39 |
39 |
$8K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
118 |
79 |
$8K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,188 |
865 |
$8K |
| 70486 |
|
28 |
28 |
$8K |
| 82728 |
|
262 |
239 |
$8K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
576 |
387 |
$7K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
3,246 |
2,600 |
$7K |
| 74022 |
|
132 |
119 |
$7K |
| 72131 |
|
31 |
28 |
$7K |
| 73564 |
|
186 |
155 |
$7K |
| 87070 |
|
229 |
194 |
$7K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
963 |
604 |
$7K |
| 72072 |
|
109 |
99 |
$7K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,476 |
1,324 |
$7K |
| 81025 |
|
787 |
629 |
$6K |
| 72100 |
|
126 |
116 |
$6K |
| 73502 |
|
168 |
157 |
$6K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
516 |
359 |
$6K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
2,125 |
1,627 |
$6K |
| 87807 |
|
79 |
72 |
$6K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
560 |
389 |
$6K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,148 |
933 |
$6K |
| 80074 |
|
26 |
24 |
$5K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
366 |
299 |
$5K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
558 |
408 |
$5K |
| 87205 |
|
397 |
331 |
$5K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
95 |
91 |
$5K |
| 82150 |
|
190 |
164 |
$5K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
803 |
414 |
$5K |
| 90715 |
|
295 |
236 |
$5K |
| 88304 |
|
135 |
78 |
$5K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
147 |
64 |
$4K |
| 87186 |
|
165 |
136 |
$4K |
| 80050 |
General health panel |
57 |
52 |
$4K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
68 |
64 |
$4K |
| 84075 |
|
196 |
146 |
$4K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
859 |
569 |
$4K |
| 73590 |
|
98 |
91 |
$4K |
| 85378 |
|
53 |
50 |
$4K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
261 |
228 |
$3K |
| 84100 |
|
271 |
215 |
$3K |
| 73090 |
|
88 |
79 |
$3K |
| J3490 |
Unclassified drugs |
2,473 |
1,204 |
$3K |
| 82248 |
|
220 |
190 |
$3K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
64 |
54 |
$3K |
| 51702 |
|
78 |
72 |
$3K |
| 93880 |
|
13 |
13 |
$3K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
54 |
51 |
$2K |
| 82140 |
|
67 |
50 |
$2K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
326 |
217 |
$2K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
55 |
50 |
$2K |
| 82043 |
|
433 |
408 |
$2K |
| 77065 |
Tomosynthesis, mammo |
28 |
27 |
$2K |
| 88342 |
|
24 |
12 |
$2K |
| 85007 |
|
156 |
120 |
$2K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
47 |
46 |
$2K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
18 |
14 |
$2K |
| 76641 |
|
18 |
18 |
$2K |
| 94060 |
|
15 |
12 |
$2K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
17 |
12 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
170 |
112 |
$1K |
| 86038 |
|
48 |
39 |
$1K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
114 |
81 |
$1K |
| 86618 |
|
61 |
28 |
$1K |
| 94761 |
|
105 |
66 |
$1K |
| 82247 |
|
87 |
64 |
$1K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
318 |
190 |
$1K |
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
279 |
274 |
$1K |
| 73080 |
|
34 |
26 |
$1K |
| 82565 |
|
72 |
44 |
$1K |
| 71100 |
|
15 |
13 |
$1K |
| J1815 |
Injection, insulin, per 5 units |
108 |
51 |
$996.89 |
| 82040 |
|
63 |
48 |
$963.88 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
146 |
117 |
$955.58 |
| 84550 |
|
65 |
60 |
$949.05 |
| 86803 |
|
31 |
28 |
$942.91 |
| 84520 |
|
44 |
31 |
$921.81 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
177 |
124 |
$773.88 |
| 80051 |
|
20 |
12 |
$755.39 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
112 |
87 |
$738.43 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
199 |
109 |
$663.34 |
| J2060 |
Injection, lorazepam, 2 mg |
171 |
131 |
$615.17 |
| 82310 |
|
20 |
12 |
$609.62 |
| 94760 |
|
241 |
126 |
$586.11 |
| 87210 |
|
13 |
13 |
$567.63 |
| 84450 |
|
18 |
13 |
$519.67 |
| 84460 |
|
18 |
13 |
$519.67 |
| 85652 |
|
101 |
96 |
$379.23 |
| J2780 |
Injection, ranitidine hydrochloride, 25 mg |
23 |
12 |
$358.27 |
| E0110 |
Crutches, forearm, includes crutches of various materials, adjustable or fixed, pair, complete with tips and handgrips |
27 |
25 |
$347.02 |
| 82746 |
|
14 |
13 |
$296.30 |
| 82977 |
|
18 |
13 |
$283.46 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
107 |
101 |
$268.77 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
16 |
15 |
$218.29 |
| 93018 |
|
27 |
25 |
$211.56 |
| 93016 |
|
27 |
25 |
$178.87 |
| J1940 |
Injection, furosemide, up to 20 mg |
101 |
56 |
$164.96 |
| 90656 |
|
29 |
29 |
$155.19 |
| J1956 |
Injection, levofloxacin, 250 mg |
41 |
28 |
$152.53 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
17 |
14 |
$139.93 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
89 |
63 |
$121.41 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
71 |
57 |
$120.53 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
16 |
14 |
$117.57 |
| 51798 |
|
16 |
14 |
$115.51 |
| A4649 |
Surgical supply; miscellaneous |
24 |
15 |
$111.18 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
12 |
12 |
$97.34 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
34 |
12 |
$67.47 |
| 99222 |
Initial hospital care, per day, moderate complexity |
16 |
16 |
$42.31 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
14 |
13 |
$34.69 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
73 |
52 |
$24.64 |
| J0456 |
Injection, azithromycin, 500 mg |
33 |
27 |
$14.21 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
63 |
63 |
$14.06 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
33 |
25 |
$11.17 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
12 |
12 |
$0.69 |
| G1010 |
Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program |
23 |
14 |
$0.03 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
112 |
98 |
$0.00 |
| 1036F |
|
112 |
98 |
$0.00 |
| Q0240 |
Injection, casirivimab and imdevimab, 600 mg |
19 |
19 |
$0.00 |
| 1123F |
|
18 |
16 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
15 |
14 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
85 |
74 |
$0.00 |
| 4004F |
|
15 |
14 |
$0.00 |
| 90653 |
|
23 |
23 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
152 |
133 |
$0.00 |
| 1124F |
|
15 |
15 |
$0.00 |